Incorporating New and Emerging Therapies Into Allergy/Immunology Practice and Research

annualmeeting.aaaaai.org

#AAAAAI21
Have ideas for sessions at the 2022 Annual Meeting? Visit annualmeeting.aaaai.org beginning February 8, 2021, to submit your proposals. The submission deadline is March 29, 2021.

#AAAAI22
Dear Colleagues,

Thank you for joining the AAAAI for the premier event in A/I—this time virtually. The live program for the 2021 Virtual Annual Meeting will take place February 26-March 1 with over 100 sessions. Most of these live sessions will be recorded and posted online for later viewing, and will include the opportunity for virtual chats for questions and answers. The live program will also be supplemented with 50 pre-recorded sessions.

The virtual platform you will log into to experience the meeting will provide access to many of the services of an in-person event, starting with a virtual lobby that will allow you to navigate according to your needs and easily access all areas in the virtual platform. Areas within the platform include the main theater (where you will access the live and pre-recorded sessions, as well as the AAAAI Business Meeting scheduled for Monday, March 1 at 7:00 pm CST), Virtual Exhibit Hall, Virtual Poster Hall, Virtual Practice Management Hub, Member Services, AAAAI Foundation resources, non-CME events, networking lounges, and more.

All content in the virtual platform will be available through March 1, 2022, so that you may continue to explore and engage as your schedule permits.

This Year’s Clinical Theme, Double the Plenaries and Keynotes, and COVID-19 Education

We are excited about this year’s clinical theme of “Incorporating New and Emerging Therapies Into Allergy/Immunology Practice and Research” and that the number of live plenary and keynote sessions being presented is double what it normally is. The Presidential Plenary, “Congenital Disorders of Immunity: How Research Drives Clinical Practice” is the first of our eight plenaries and takes place Friday, February 26 at 11:10 am CST. Our two keynotes addressing “The Biomedical Research Response to COVID-19: A View from NIAID” and “NAEPP Expert Panel Report on Selected Topics in Asthma Management 2020” are scheduled for Saturday, February 27 and Sunday, February 28, respectively, at 11:10 am CST. Aside from the Saturday keynote, there are other sessions on timely topics related to COVID-19, including immune profiling of COVID-19 patients, when and how to test COVID-19 patients for underlying immunodysregulatory conditions, and lessons learned from the pandemic.

We invite you to browse the Education At-A-Glance pages of this Final Program, which first lists all the pre-recorded sessions that you can watch at your convenience and then lists the lineup of live sessions.

Support A/I Research at the AAAAI Foundation Virtual Events

The Virtual Awards Celebration on Friday, February 26, jointly hosted by the AAAAI and AAAAI Foundation, will feature the President and President-Elect Reception, Honorary Awards Luncheon and the AAAAI Foundation Benefit as one exciting presentation. There will also be an option to make a gift during the event to support our GAIN Campaign and be recognized in real-time. The Virtual Awards Celebration is open to all Virtual Annual Meeting participants and no registration is necessary.

In addition, the Foundation is hosting a Virtual Run/Walk over March 1-14 to support allergy/immunology research. Instead of running a predetermined distance at one time, this event allows participants to run or walk at their own pace, on their own time, anywhere. There is also an option to compete and fundraise. Visit aaaaifoundation.org/special-events for more details and to register for the Virtual Run/Walk.

We realize this will not be a typical Annual Meeting due to the pandemic. Yet we are confident you will still experience a world-class educational program covering the latest in our field that will allow you to meet, and likely exceed, the CME requirements needed for MOC. And if you post on social media during the Virtual Annual Meeting, be sure to use our #AAAAI21 hashtag so that patients and other colleagues can follow along and see what you are learning.

Sincerely,

Mary Beth Fasano, MD MSPH FAAAAI
AAAAI President

Leonard B. Bacharier, MD FAAAAI
Chair, Annual Meeting Program Committee

The AAAAI Virtual Annual Meeting is not a public event. Programs presented at the Virtual Annual Meeting are for the education of attendees and purchasers of recorded presentations as authorized by the AAAAI. Any use of program content, the name of a speaker and/or program title, or the name of the AAAAI without the written consent of the AAAAI is prohibited. The “program content” includes, but is not limited to, oral presentations, audio visual materials used by the speakers and program handouts. This rule applies before, during and/or after the meeting.

The AAAAI endorses only those activities described in this printed program. Any other events occurring during the AAAAI Virtual Annual Meeting are not sanctioned by the AAAAI.
#RunWithAAAAI

Support A/I Research by participating in the AAAAI Foundation’s Virtual Run/Walk. Compete for fastest 5K, most miles logged over two weeks or highest fundraising amount.

Sign up now and participate anywhere in the world March 1-14.

Visit https://p2p.onecause.com/aaaairun for more information and to register today!

Sponsored by

Virtual AWARDS CELEBRATION

HOSTED JOINTLY BY THE AAAAI & AAAAI FOUNDATION

FRIDAY, FEBRUARY 26
6PM CST

Proudly supported by

Genentech
A Member of the Roche Group
AAAII Exhibits

AAAII Journals
View extensive Journal resources and chat with key representatives from *The Journal of Allergy and Clinical Immunology (JACI)* and *JACI: In Practice*, two of the most highly-cited and widely read allergy/immunology journals.

Education Station
Visit the AAAAI Education Station to:
- Learn how to claim credit
- Explore CME and MOC opportunities
- Suggest future topics for AAAAI activities

**Education Station Hours**
- Friday, February 26: 8:00 am to 5:00 pm
- Saturday, February 27: 8:00 am to 5:30 pm
- Sunday, February 28: 8:00 am to 5:30 pm
- Monday, March 1: 8:00 am to 3:30 pm

Member Resource Center
Visit the AAAAI Member Resource Center to:
- Learn how to become a member
- Update your membership information
- Inquire about your membership/application status

**Member Resource Center Hours**
- Friday, February 26: 7:30 am to 6:00 pm
- Saturday, February 27: 7:30 am to 5:15 pm
- Sunday, February 28: 7:30 am to 5:15 pm
- Monday, March 1: 7:30 am to 4:15 pm

Practice Management Hub
The Practice Management Hub is your one-stop shop for practical tools and resources for the key issues facing allergy practices right now. Live chat with practice management experts everyday on topics such as telemedicine, compounding and the AAAAI COVID-19 Response Task Force.

**Practice Management Hub Hours**
- Friday, February 26: 8:00 am to 5:00 pm
- Saturday, February 27: 8:00 am to 5:00 pm
- Sunday, February 28: 8:00 am to 5:00 pm
- Monday, March 1: 8:00 am to 3:00 pm

Abstracts
Abstracts programmed at the Virtual Annual Meeting were published as an online supplement to *The Journal of Allergy and Clinical Immunology (JACI)* and can be accessed on the JACI website, jacionline.org.

American Academy of Allergy, Asthma & Immunology Foundation (AAAII Foundation)
*Funding research that leads to the prevention and cure of asthma and allergic and immunologic disease.*

Visit with us at our virtual booth for exciting news and updates:
- 2021 Faculty Development Awardees
- 2021 Lecturehip Honorees
- 2021 Special Events: Virtual Awards Celebration and Virtual Run/Walk

Education Sessions
The majority of education sessions do not require pre-registration; however, seminars require separate registration and have limited space available. The registration confirmation email provides a link to register for seminars. Please be advised that these sessions have an additional registration fee and are available on a first-come, first-served basis.

Evaluations
Participants will be asked to provide input on the educational program of the Virtual Annual Meeting through the online credit claiming system when claiming credit for participation, as well as when viewing individual education sessions.

Exhibitor Directory
*Sponsored by Regeneron and Sanofi Genzyme*
Our Exhibitor Directory provides both an alphabetical and a product/service index for the Virtual Annual Meeting exhibitors. Full contact information for each exhibitor will be included. This valuable resource will be available on the AAAAI Virtual Annual Meeting website and in our virtual platform.

Exhibits
Our Virtual Annual Meeting will include exhibit halls where you can engage with the exhibiting companies and organizations to learn the latest information on products and services available to physicians, researchers and allied health professionals in the field of allergy/immunology.

Please allow adequate time in your daily schedule to visit the virtual exhibits and speak with representatives of companies that provide services or market products directly related to your professional interests.

**Exhibit Hours**
- Friday, February 26: 8:00 am to 7:00 pm
- Saturday, February 27: 8:00 am to 6:25 pm
- Sunday, February 28: 8:00 am to 6:25 pm
- Monday, March 1: 8:00 am to 4:00 pm

Handouts
Handouts for education sessions will be available in the session descriptions in the Online Planner, accessible from within the Virtual Annual Meeting platform or the Annual Meeting website.

All times are listed in Central Standard Time (CST)
Meeting Information

All times are listed in Central Standard Time (CST)

Networking Lounges
Join us in all of our networking lounges to meet and engage with your colleagues. There are several lounges to choose from, so be sure to add time to your schedule to check them out and engage with other professionals.

AAAAI Networking Lounge
Allied Health Networking Lounge
Sponsored by Aimmune Therapeutics
ORLADEYO™ (berotralstat) Networking Lounge
Sponsored by BioCryst
FIT Networking Lounge
Sponsored by DBV Technologies
NAIA Networking Lounge
Sponsored by Amgen and AstraZeneca
Oral Abstract Networking Lounge

Recording of Sessions
Many of the scientific sessions will be recorded as part of the Virtual Annual Meeting and will be available for viewing on the Virtual Annual Meeting website through March 1, 2022. Individual recording of educational sessions is not permitted.

AAAAI Annual Business Meeting
Monday, March 1, 7:00 to 8:00 pm CST

All AAAAI Fellows and members should attend the Annual Business Meeting. No fee. No pre-registration required.
### Non-CME Educational Programs

#### Friday

**These programs are not sponsored or programmed by the AAAAI.**

**Break Through the Noise and Focus on Type 2 Inflammation in Certain Diseases, Including Eosinophilic Esophagitis**

Friday, February 26, 6:00 to 7:45 am Central  
*Sponsored by Sanofi Genzyme and Regeneron.*

**Faculty:** Joshua S. Jacobs, MD; Jivianne T. Lee, MD FACS; Joshua B. Weschler, MD MSCI

Join us as we review recent data on Type 2 inflammation. During the first half of this program, watch an expert explore Type 2 inflammation as a contributor to potentially coexisting conditions, including asthma, chronic rhinosinusitis with nasal polyposis, atopic dermatitis, and eosinophilic esophagitis (EoE). Stay with us as we walk through the implications of coexisting Type 2 inflammatory diseases – such as greater disease severity and worse disease control. The second half of this presentation will focus on EoE: disease presentation, symptoms, and additional details on the role of Type 2 inflammation in epithelial barrier dysfunction, allergic inflammation, and eosinophilic inflammation associated with EoE.

**Targeting a Common Contributor to Severe Asthma**

Friday, February 26, 6:00 to 8:00 pm Central  
*Sponsored by AstraZeneca.*

You are cordially invited to view a program to learn about severe eosinophilic asthma and the clinical effect of a targeted biologic treatment option. The program will review its impact on exacerbations, lung function, and reducing oral corticosteroids in patients with severe eosinophilic asthma. Listen to an expert to explore its clinical efficacy, mechanism of action, and safety profile data.

**The Journey Towards Controlled Asthma – One Step at a Time**

Friday, February 26, 6:00 to 8:00 pm Central  
*Sponsored by GSK.*

**Speakers:** William Busse, MD; Jonathan Corren, MD

A goal of asthma treatment is to achieve and maintain control. However, uncontrolled asthma remains common and often goes unrecognized by patients and providers. Uncontrolled asthma impacts patient quality of life, mortality, and healthcare resources. Increasing awareness of the challenges faced by patients and providers may help identify appropriate treatment options, help reduce disease burden and improve patient outcomes. This program will: 1) provide insight regarding the burden of uncontrolled asthma, 2) review asthma management guidelines, and 3) identify ways to customize management by pairing the right medications with appropriate patients. This is a non-CME program sponsored by GSK.

Registration link: https://bit.ly/38zgXvJ

#### Saturday

**Recognizing the Rare: Diseases of Hypereosinophilia Including Differentiation of Etiology, Burden, and Management with Clinical Case Examples**

Saturday, February 27, 7:00 am to 9:00 am Central  
*Sponsored by GSK.*

**Moderator:** Thomas Corbridge, MD  
**Speakers:** Anna Kovalszki, MD; Sameer Mathur, MD PhD

Program Description: Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangitis (EGPA) are rare diseases driven by increased eosinophils. Both have diverse and potentially overlapping clinical presentations that can affect a broad range of organ systems and complicate differential diagnosis. In this program, a panel of experts will present key information regarding the presentation and differential diagnosis of HES and EGPA. They will also discuss patient cases and provide expert insight on diagnosis, clinical burden, and how multidisciplinary care is essential. These factors are critical for ensuring optimal patient care and to minimize symptom burden and disease progression.


---

**Atopic Dermatitis: A Disease with Underlying Inflammation and Visible Burden**

Friday, February 26, 6:00 to 7:00 pm Central  
*Sponsored by Regeneron and Sanofi Genzyme.*

**Faculty:** Autumn Burnette, MD FACAAI

Come learn about the characteristic features, burden, and evolving management strategies in atopic dermatitis, as well as the type 2-driven immune dysregulation and underlying inflammation associated with the disease.

Program link: http://bit.ly/3qHNYfy

**The Power of Proven Prevention for Patients With Hereditary Angioedema (HAE)**

Friday, February 26, 6:00 to 8:00 pm Central  
*Sponsored by Takeda. Industry Program. No CME/CE credit can be claimed.*

**Faculty:** Douglas Johnston, DO, and Andrew Smith, MD

Join us to rediscover what attack prevention can mean for your patients with hereditary angioedema (HAE). Expert faculty will guide you through clinical trial data as well as the latest data from our open-label extension study, highlighting the importance of proven prevention. This will be followed by a discussion between physicians about one of their patients who is living with HAE.
**A Unique, Interactive Experience that Brings to Life the Role of Type 2 Inflammation in Asthma, Chronic Rhinosinusitis With Nasal Polyposis, and Atopic Dermatitis**

Saturday, February 27, 7:00 to 9:00 am Central  
**Sponsored by Sanofi Genzyme and Regeneron.**  
**Faculty:** Joseph K. Han, MD; Robert Sporter, MD  
Go beyond the standard didactic presentation and watch our experts come to life on your screen to demonstrate how 3 key components of Type 2 inflammation – epithelial barrier dysfunction, allergic inflammation, and eosinophilic inflammation – may contribute in part to asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and atopic dermatitis (AD). Our experts will apply these concepts into their case-based review of patients with asthma or CRSwNP.

**TSPL: A Key Epithelial Cytokine at the Top of the Asthma Inflammatory Cascade**

Saturday, February 27, 6:30 to 8:30 pm Central  
**Sponsored by Amgen and AstraZeneca.**  
**Speakers:** Joan Reibman, MD; Geoffrey Chupp, MD; Diego Maselli Caceres, MD  
Is there a novel way to think about asthma inflammation? Join a panel of leading expert physicians to discuss 1) the role of the airway epithelium and epithelial cytokines (alarmins) in asthma, 2) the role of thymic stromal lymphopoietin (TSLP) as a key driver of multiple types of asthma inflammation, and 3) patient cases describing the potential clinical relevance of TSLP in asthma. This will be an opportunity to engage experts to think differently about asthma.

**For hereditary angioedema (HAE), This Is Big: Learn About a New Prophylactic Therapy**

Saturday, February 27, 6:30 to 7:30 pm Central  
**Sponsored by BioCryst Pharmaceuticals, Inc.**  
Join us for a dynamic presentation where we’ll explore the burden of treatment for patients with HAE. Expert faculty will present the clinical profile of a new prophylactic therapy for HAE, the route of administration, and its safety and efficacy data. Learn how to initiate therapy and the support services available to you and your patients. This presentation will be followed by a live Q&A with the faculty. An HAE program not to be missed!  
Visit www.ThisIsBigHAEwebinar.com to register now!

**Asthma Experts Discuss a Biologic Agent and an Inhaled Therapy**

Saturday, February 27, 6:30 to 8:30 pm Central  
**Sponsored by GSK.**  
Join Drs. Lawrence DuBuske, Ellen Sher, and Stanley Goldstein during this 2-hour, 2-presentation session to discuss treatment approaches with live Q&A at the end of each session. 1) At 6:30pm CT, explore clinical features of patients with severe eosinophilic asthma and review clinical data for a targeted biologic agent, including long-term and real-world evidence, and 2) At 7:30pm CT, review practical approaches to identify adult patients with asthma who remain symptomatic while receiving maintenance therapy and recently published evidence for the use of inhaled triple therapy.

**Moderate-to-Severe Atopic Dermatitis: Targeting the Underlying Inflammatory Processes to Improve Patient Outcomes**

Saturday, February 27, 6:30 to 7:30 pm Central  
**This activity is provided by Med Learning Group.**  
**This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).**  
**This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.**  
Join Dr. Peter Lio and Dr. Mark Boguniewicz in this interactive, case-based program about the underlying causes of atopic dermatitis along with current and emerging systemic agents as part of the overall treatment plan. Further, through the use of 2D and 3D animations, this program aims to engage patients with atopic dermatitis and caregivers in their care by viewing disease pathophysiology and how possible treatment options work, which could bolster patient commitment and adherence to their treatment plans.  

**Sunday**

These programs are not sponsored or programmed by the AAAAI.

**Expert Perspectives on Lower and Upper Airways Disease - From Pathophysiology to Patient Care**

**Part 1:** Kathleen Buchheit, MD; Whitney Stevens, MD; Delvyani Lal, MD  
**Moderator:** Larry Borish, MD  
**Part 2:** Steven Ackerman, PhD; Autumn Burnette, MD; Thomas Casale, MD; Jonathan Corren, MD; Flavia Hoyte, MD; Katharine Woesnner, MD  
**Moderator:** Thomas Corbridge, MD  
**Descriptions:**  
Part 1: Chronic inflammatory upper airway diseases, such as chronic rhinosinusitis with or without nasal polyps (CRS, CRSwNP), have complex, heterogenous pathophysiologies relevant for disease trajectory and patient care. An ever-evolving body of research has elucidated dynamic pathways underlying the manifestation of CRS and CRSwNP. This expert panel will explore the complexities of immune pathophysiology, illustrate important unknowns, and highlight research that may influence how patients are diagnosed and managed.  
Part 2: Chronic inflammatory disease of the lower airway includes severe eosinophilic asthma (SEA), a subset of severe asthma driven by elevated eosinophils. In this symposium, three panels of experts will address the complexities of managing this patient population with high unmet need, by highlighting the eosinophilic phenotype, reliance on OCS in uncontrolled disease, and management considerations of patients with challenging comorbidities.  
**Registration link:** https://bit.ly/2Lhqd7W
Non-CME Educational Programs

Pathophysiology of Atopic Dermatitis
Sunday, February 28, 8:00 am to 9:00 am Central
Sponsored by Regeneron and Sanofi Genzyme.
Faculty: Neal Jain, MD FACAAI FAAAAI
Come learn more about the pathophysiology of atopic dermatitis. Also, hear about a treatment that may help your appropriate atopic dermatitis patients with uncontrolled moderate-to-severe atopic dermatitis.
Program link: http://bit.ly/3qG7E3d

Evidence-Based Treatment Approach for Peanut Allergy in Children
Sunday, February 28, 6:30 to 8:30 pm Central
Sponsored by Aimmune Therapeutics, a Nestlé Health Science Company.
Peanut allergy can significantly impact patients’ lives. With PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp], you have the option of providing your patients with the first FDA-approved treatment for peanut allergy. Please join Gregory W. Bensch, MD, Joel M. Hartman, MD, and Ellen R. Sher, MD as they review the clinical safety and efficacy of PALFORZIA and share their experience using this therapy for their patients.

Exploring the Constellation of Eosinophilic Immune Dysfunction
Sunday, February 28, 6:30 to 8:30 pm Central
Sponsored by AstraZeneca Pharmaceuticals, LP.
Speaker: Jonathan Bernstein, MD, Professor of Medicine, University of Cincinnati, Department of Internal Medicine, Division of Immunology, Allergy Section
Join us for an educational program that will provide an overview of eosinophilic immune dysfunction, which can be characterized as the dysregulation of biological mechanisms involved with eosinophil recruitment and activation that is seen across a range of diseases.

Systemic Mastocytosis: Unraveling a Medical Mystery
Sunday, February 28, 6:30 to 8:30 pm Central
Sponsored by Blueprint Medicines.
Faculty: Cem Akin, MD PhD
Join us to hear Dr Cem Akin discuss how to identify patients with systemic mastocytosis (SM) in your clinical practice. Patients with SM experience a wide range of symptoms and can be difficult to diagnose. Consequently, one study showed the median time from symptom onset to diagnosis is approximately seven years. Furthermore, living with SM can adversely impact quality of life, and therapeutic options are limited. This session will cover key topics in SM, including the role of KIT D816V mutation as a central driver of disease, hallmark symptoms, diagnostic work-up, and treatment options for patients with SM.
https://smsymposia.com/

Eosinophilic Esophagitis: Improving Outcomes in Pediatric and Adult Patients Through Earlier Diagnosis and Treatment – An Innovative Whiteboard View
Sunday, February 28, 6:30 to 7:30 pm Central
This activity is provided by Med Learning Group.
This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Faculty: Matthew Greenhawt, MD, Director, Food Challenge and Research Unit, Children’s Hospital Colorado, Aurora, CO
Ikuo Hirano, MD, Professor of Medicine, Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Eosinophilic esophagitis (EoE) is a major etiology for dysphagia, food impaction and regurgitation. Triggered by exposure to antigens, EoE is best co-managed by gastroenterologists and allergists. This program will be presented by two co-authors of the EoE guideline that was jointly issued by the American Gastroenterological Association and AAAAI/ACAAI in 2020. All aspects of EoE diagnosis and management (both pharmacological and non-pharmacological) are covered in the agenda. The session will include animated whiteboards, resulting in an engaging and memorable experience for the learner.
To register: WWW.MLG-EE.COM

Monday
These programs are not sponsored or programmed by the AAAAI.

Deepening Our Understanding: Cytokine Signaling and the JAK/STAT Pathway in Atopic Dermatitis
Monday, March 1, 8:15 to 9:00 am Central
Sponsored by Pfizer Inc.
Presented by: Lee S. Clore, Jr, MD, Allergy and Asthma Specialists, PSC, Secretary/Treasurer Southeastern Allergy Asthma and Immunology Society (SEAAIS), Owensboro, Kentucky
Pfizer invites you to an unbranded symposium during which our allergy immunology expert will review the disease state and burden of atopic dermatitis (AD), discuss the integral components in the pathophysiology of AD, and describe the role of the JAK/STAT pathway in AD. This program will conclude with a question-and-answer session.
https://smsymposia.com/
Striving for Control: Taming Moderate to Severe Childhood Asthma in the Biologics Age

Monday, March 1, 7:00 to 9:00 am Central
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Twenty-five million people in the United States suffer from asthma; over 6 million are children and as many as 10% of children with asthma have severe disease. Recent new and exciting developments in biologic treatments for children with moderate to severe asthma are expanding our opportunities to optimize therapy and improve patient quality of life.

This innovative virtual symposium uses interactive infographics to address our evolving understanding of asthma pathophysiology and its implications for treatment planning. Use the platform to interact with animated educational content as faculty guide you through management approaches and case challenges.

Signals of Change in the Management of Atopic Dermatitis

Monday, March 1, 4:15 to 6:15 pm Central
Supported by an educational grant from Pfizer Inc.

Atopic dermatitis affects nearly 18% of children and 10% of adults and can have a substantial negative impact on the quality of life of patients and families. Management is challenging at any age, with patients and caregivers often becoming overwhelmed by the chronic, relapsing nature of AD. Disease severity is essential in informing treatment decisions, as is new clinical trial data for therapies such as oral JAK inhibitors.

This virtual symposium will assist learners in applying clinical tools to establish disease severity, translating how new agents will impact practice, and integrating patient preferences and treatment goals into shared decision-making.

See EoE: A Multidisciplinary Approach to Diagnosing and Managing Eosinophilic Esophagitis

Monday, March 1, 4:15 to 6:15 pm Central
Sponsored by Takeda Pharmaceuticals U.S.A., Inc.

Potential Panelists: Jonathan Spergel, MD PhD; Gary Falk, MD

Join us for an engaging, expert-led discussion on eosinophilic esophagitis (EoE). A multidisciplinary panel will review the definition and epidemiology of EoE, evaluate the pathophysiology of the disease, clinical presentations, and share their collective perspectives on the latest guideline recommendations for diagnosis and management. An opportunity for interactive Q&A with the expert panel will follow the presentation.
Two types of continuing education credit will be available at the 2021 AAAAI Virtual Annual Meeting: AMA PRA Category 1 CME Credits™ for physicians and Continuing Education (CE) contact hours for nurses. Credit claiming will be available through March 1, 2022.

Physicians – Continuing Medical Education (CME) Credits

Accreditation Statement
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
The AAAAI designates this Other activity (combination of live and pre-recorded online content) for a maximum of 166.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association has determined that physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 Credits™.

Target Audience
The AAAAI Annual Meeting is designed for clinicians, researchers, trainees/students and allied health professionals involved and/or interested in the study of allergy, asthma and immunology.

Program Objective
Upon completion of the AAAAI Annual Meeting, participants should be able to discuss the latest advances in the research, diagnosis and treatment of allergic and immunologic disease. Please refer to the individual session descriptions on the Virtual Annual Meeting website for session-specific learning objectives.

ABAI – Continuing Medical Education (CME) Credits

The American Board of Allergy and Immunology (ABAI) requires diplomates to attest to obtaining 25 AMA PRA Category 1 CME Credits™ in allergy/immunology each year. AAAAI reports all CME credits it issues to physician learners to the ABAI on a quarterly basis, to be posted in learners’ diplomat portals. For more information about credit requirements for ABAI Maintenance of Certification visit the ABAI website at https://abai.org/cme.asp.

Allied Health – Continuing Education (CE) Credits

Nurses – Continuing Education (CE) Contact Hours
The American Academy of Allergy, Asthma & Immunology (AAAAI) is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 166.00 Contact Hours.

Medical Administrators
Practice administrators who attend the 2021 AAAAI Virtual Annual Meeting may apply for credit through the American College of Medical Practice Executives (ACMPE). For additional information, please contact the Medical Group Management Association at www.mgma.com.

Advanced Practitioners
The AAPA, ANCC and AANP accept reports from advanced practitioners of their participation in activities offering AMA PRA Category 1 Credits™ for continuing education and credentialing purposes. For more information, please contact the appropriate organization.

Pharmacists
Pharmacists are encouraged to contact their state boards of pharmacy to determine if reports of participation in the 2021 AAAAI Virtual Annual Meeting are accepted for re-licensure.

Registered Dietitians
The Commission on Dietetic Registration accepts reports from registered dietitians of their participation in activities offering AMA PRA Category 1 Credits™ for continuing education and credentialing purposes. Contact the CDR for details on how to report your completion of these activities.

Target Audience
Health care professionals who assist with and provide care to persons with asthma, allergic and immunologic diseases, specifically: RNs, LPNs, nurse practitioners, physician assistants, respiratory therapists, medical technologists, medical assistants, clinical research coordinators, and practice managers/administrators.

Learning Objectives
Upon completion of the AAAAI Annual Meeting, participants should be able to discuss and expand upon the latest advances in medications, equipment and procedures necessary to promote health for their patients; describe and discuss new therapies, information, patient care and education in the field of allergy, asthma and immunology; identify new approaches to clinical research which will improve efficiency and effectiveness; and discuss coding and other administrative aspects of a medical practice. Please refer to the individual session descriptions on the Virtual Annual Meeting website for session-specific learning objectives.
## Pre-Recorded Sessions

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>0101</td>
<td>ABAI Continuous Assessment Program (CAP) Literature Review Course</td>
</tr>
<tr>
<td>0102</td>
<td>One Size Does Not Fit All: Precision Medicine in Allergic Disease and Primary Immunodeficiencies (PID)</td>
</tr>
<tr>
<td>0103</td>
<td>An Update on Biologic Therapies for Allergic and Immunologic Conditions</td>
</tr>
<tr>
<td>0104</td>
<td>Fungal Exposure and Respiratory Health: Insights into Fungal Aeroallergen Sources, Their Clinical Relevance and Treatment Options, and Practical Applications for the Allergist/Immunologist</td>
</tr>
<tr>
<td>0105</td>
<td>Multidisciplinary Approach to Systemic Mastocytosis</td>
</tr>
<tr>
<td>0106</td>
<td>Allied Health Advanced Practice Course: Health Literacy in the Age of the Internet: Combating Dr. Google</td>
</tr>
<tr>
<td>0201</td>
<td>Telemedicine and Drug Allergy</td>
</tr>
<tr>
<td>0202</td>
<td>Targeting Metabolic Pathways in Asthma</td>
</tr>
<tr>
<td>0203</td>
<td>Challenges in Urban and Rural Environmental Influencers in Asthma</td>
</tr>
<tr>
<td>0204</td>
<td>Personalized Medicine in Immunology: How Close are We to Harnessing the Power of T-Cells?</td>
</tr>
<tr>
<td>0205</td>
<td>Treatment of Aspirin-Exacerbated Respiratory Disease (AERD) in the Age of Biologics</td>
</tr>
<tr>
<td>0206</td>
<td>New Insights into Pet Allergy</td>
</tr>
<tr>
<td>0207</td>
<td>Spectrum of Occupational Exposure Effects with Asthma: Implications for Diagnosis and Biologic Therapeutics</td>
</tr>
<tr>
<td>0208</td>
<td>Eosinophilic Esophagitis (EoE): Novel Endotypes and Approaches to Management</td>
</tr>
<tr>
<td>0209</td>
<td>Memory and Tolerance in Food Allergy</td>
</tr>
<tr>
<td>0210</td>
<td>Innovative Approaches to Improving Asthma Control</td>
</tr>
<tr>
<td>0211</td>
<td>Keeping Up with Ever-Changing Clinical Guidelines: The Latest from the Joint Task Force on Practice Parameters</td>
</tr>
<tr>
<td>0212</td>
<td>Phenotyping Aspirin-Exacerbated Respiratory Disease (AERD): Heterogeneity of Nasal Polyps and the Role of Atopy in Aspirin-Exacerbated Respiratory Disease Patients</td>
</tr>
<tr>
<td>0213</td>
<td>Cysteinyl Leukotrienes: Beyond Bronchoconstriction</td>
</tr>
<tr>
<td>0214</td>
<td>Immunodysregulation, Immunometabolism, and B Cells: Research from the 2018 AAAAI Foundation Faculty Development Awardees</td>
</tr>
<tr>
<td>0301</td>
<td>Penicillin Allergy: An Old Problem with New Solutions</td>
</tr>
<tr>
<td>0302</td>
<td>Identifying and Correcting Dysfunctional Breathing Techniques in Athletes with Asthma</td>
</tr>
<tr>
<td>0303</td>
<td>Vaccination and the Allergist/Immunologist</td>
</tr>
<tr>
<td>0304</td>
<td>From Early Life Infections to Childhood Asthma: Hot Topics</td>
</tr>
<tr>
<td>0305</td>
<td>Cannabis Exposure and its Impact on Human Respiratory Health: Adjusting to the New Reality</td>
</tr>
<tr>
<td>0306</td>
<td>Patient with Elevated Tryptase: Differential Diagnosis and Management</td>
</tr>
<tr>
<td>0307</td>
<td>Allergic Disease, Farms and Hygiene: An Update</td>
</tr>
<tr>
<td>0308</td>
<td>Allied Health: Deficient T-Cell Receptor Excision Circles (TRECs) and Beyond</td>
</tr>
<tr>
<td>0309</td>
<td>Food Protein-Induced Enterocolitis Syndrome (FPIES): Emerging Trends, Treatments and Advances</td>
</tr>
<tr>
<td>0310</td>
<td>Oral Immunotherapy (OIT): Who and Why</td>
</tr>
<tr>
<td>0311</td>
<td>Allied Health: The Burden of Non-Immunoglobulin E (IgE)-Mediated Food Allergies</td>
</tr>
<tr>
<td>0312</td>
<td>Allied Health: Wheat Allergy or Gluten Intolerance: Sifting the Facts</td>
</tr>
<tr>
<td>0313</td>
<td>Patients with Food Allergies Need to Avoid Packaged Food Products with Precautionary Labeling</td>
</tr>
<tr>
<td>0314</td>
<td>Single Maintenance and Reliever Therapy (SMART) Should be Implemented for All Patients with Asthma</td>
</tr>
<tr>
<td>0315</td>
<td>Concerns and Controversies of Vaping</td>
</tr>
<tr>
<td>0316</td>
<td>Use of Dupilumab vs. Surgery in Management of Chronic Rhinosinusitis with Nasal Polyps</td>
</tr>
<tr>
<td>0317</td>
<td>ADDA: Epinephrine for Anaphylaxis: What Do We Know and What Do We Need?</td>
</tr>
<tr>
<td>0318</td>
<td>ADT: Biologics in Asthma Endotypes: Focus on Aspirin-Exacerbated Respiratory Disease and Allergic Bronchopulmonary Aspergillosis</td>
</tr>
<tr>
<td>0319</td>
<td>BCI: Precision Medicine in Primary Immunodeficiency: Are We There Yet?</td>
</tr>
<tr>
<td>0320</td>
<td>EORD: The Increasing Complexity of the Environment: Homogenized “Dead” Milk, Tick Bites and Dust Mites Produce Different Immunological and Clinical Outcomes</td>
</tr>
<tr>
<td>0321</td>
<td>FAED: Tough Nut to Crack: Insights Into Diagnosis and Immunotherapy for Food Allergy</td>
</tr>
</tbody>
</table>
### Pre-Recorded Sessions, continued

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>0505</td>
<td>MAAI: The Role of the Microbiome in Allergic Disease</td>
</tr>
<tr>
<td>0506</td>
<td>HEDQ: Actionable Ways to Improve Wellness for Allergy/Immunology Clinicians</td>
</tr>
<tr>
<td>0507</td>
<td>IRSO: Rhinitis and Rhinosinusitis: Looking Back and Looking Forward</td>
</tr>
</tbody>
</table>

#### Friday, February 26, 2021

*All times are listed in Central Standard Time (CST)*

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1101</td>
<td>Friday, February 26, 2021, 8:00 to 11:00 am</td>
</tr>
<tr>
<td>1102</td>
<td>Friday, February 26, 2021, 8:00 to 11:00 am</td>
</tr>
<tr>
<td>1103</td>
<td>Friday, February 26, 2021, 8:00 to 11:00 am</td>
</tr>
<tr>
<td>1104</td>
<td>Friday, February 26, 2021, 8:00 to 11:00 am</td>
</tr>
<tr>
<td>1105</td>
<td>Friday, February 26, 2021, 8:00 to 11:00 am</td>
</tr>
<tr>
<td>1106</td>
<td>Friday, February 26, 2021, 11:10 am to 12:40 pm</td>
</tr>
<tr>
<td>1107</td>
<td>Friday, February 26, 2021, 1:10 to 2:40 pm</td>
</tr>
<tr>
<td>1108</td>
<td>Friday, February 26, 2021, 2:50 to 4:05 pm</td>
</tr>
<tr>
<td>1109</td>
<td>Friday, February 26, 2021, 2:50 to 4:05 pm</td>
</tr>
<tr>
<td>1110</td>
<td>Friday, February 26, 2021, 2:50 to 4:05 pm</td>
</tr>
<tr>
<td>1111</td>
<td>Friday, February 26, 2021, 2:50 to 4:05 pm</td>
</tr>
<tr>
<td>1112</td>
<td>Friday, February 26, 2021, 2:50 to 4:05 pm</td>
</tr>
<tr>
<td>1113</td>
<td>Friday, February 26, 2021, 2:50 to 4:05 pm</td>
</tr>
<tr>
<td>1114</td>
<td>Friday, February 26, 2021, 2:50 to 4:05 pm</td>
</tr>
</tbody>
</table>

#### Saturday, February 27, 2021

*All times are listed in Central Standard Time (CST)*

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>Saturday, February 27, 2021, 8:00 to 9:00 am</td>
</tr>
<tr>
<td>2002</td>
<td>Saturday, February 27, 2021, 8:00 to 9:00 am</td>
</tr>
<tr>
<td>2003</td>
<td>Saturday, February 27, 2021, 8:00 to 9:00 am</td>
</tr>
<tr>
<td>2004</td>
<td>Saturday, February 27, 2021, 8:00 to 9:00 am</td>
</tr>
<tr>
<td>2005</td>
<td>Saturday, February 27, 2021, 8:00 to 9:00 am</td>
</tr>
<tr>
<td>2006</td>
<td>Saturday, February 27, 2021, 8:00 to 9:00 am</td>
</tr>
<tr>
<td>2101</td>
<td>Saturday, February 27, 2021, 9:10 to 10:40 am</td>
</tr>
<tr>
<td>2301</td>
<td>Saturday, February 27, 2021, 11:10 am to 12:10 pm</td>
</tr>
<tr>
<td>2401</td>
<td>Saturday, February 27, 2021, 12:20 to 1:35 pm</td>
</tr>
</tbody>
</table>
# Education At-A-Glance

## Saturday, February 27, 2021, continued

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Session Title</th>
<th>Date Time</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2402</td>
<td>National Institute of Allergy and Infectious Diseases (NIAID): New Insights into the Origins of Childhood Asthma</td>
<td>Saturday, February 27, 2021, 12:20 to 1:35 pm</td>
<td>National Institute of Allergy and Infectious Diseases (NIAID): New Insights into the Origins of Childhood Asthma</td>
</tr>
<tr>
<td>2403</td>
<td>COVID-19 and Pulmonary Manifestations in Different Populations</td>
<td>Saturday, February 27, 2021, 12:20 to 1:35 pm</td>
<td>COVID-19 and Pulmonary Manifestations in Different Populations</td>
</tr>
<tr>
<td>2404</td>
<td>Update on Autoinflammatory Disorders</td>
<td>Saturday, February 27, 2021, 12:20 to 1:35 pm</td>
<td>Update on Autoinflammatory Disorders</td>
</tr>
<tr>
<td>2405</td>
<td>Primary Disorders of Mast Cells: More Common Than You Thought</td>
<td>Saturday, February 27, 2021, 12:20 to 1:35 pm</td>
<td>Primary Disorders of Mast Cells: More Common Than You Thought</td>
</tr>
<tr>
<td>2406</td>
<td>Allied Health: Managing Your Food Allergy Patient in Clinical Practice from Infancy through Childhood</td>
<td>Saturday, February 27, 2021, 12:20 to 1:35 pm</td>
<td>Allied Health: Managing Your Food Allergy Patient in Clinical Practice from Infancy through Childhood</td>
</tr>
<tr>
<td>2501</td>
<td>Environmental Change and the Outpaced Immune System: The Effect on Allergic Sensitization</td>
<td>Saturday, February 27, 2021, 1:45 to 3:15 pm</td>
<td>Environmental Change and the Outpaced Immune System: The Effect on Allergic Sensitization</td>
</tr>
<tr>
<td>2701</td>
<td>Contact Dermatitis in the Patient with Atopic Dermatitis</td>
<td>Saturday, February 27, 2021, 3:45 to 4:45 pm</td>
<td>Contact Dermatitis in the Patient with Atopic Dermatitis</td>
</tr>
<tr>
<td>2702</td>
<td>Confounders of Mast Cell Activation Syndrome (MCAS): Approaches to the Symptomatic Patient When the Criteria for MCAS Are Not Met</td>
<td>Saturday, February 27, 2021, 3:45 to 4:45 pm</td>
<td>Confounders of Mast Cell Activation Syndrome (MCAS): Approaches to the Symptomatic Patient When the Criteria for MCAS Are Not Met</td>
</tr>
<tr>
<td>2703</td>
<td>Allied Health: Helping Patients Cope with Allergic Reactions</td>
<td>Saturday, February 27, 2021, 3:45 to 4:45 pm</td>
<td>Allied Health: Helping Patients Cope with Allergic Reactions</td>
</tr>
<tr>
<td>2704</td>
<td>Lessons Learned from Severe Asthma Clinics: An Interdisciplinary Approach</td>
<td>Saturday, February 27, 2021, 3:45 to 4:45 pm</td>
<td>Lessons Learned from Severe Asthma Clinics: An Interdisciplinary Approach</td>
</tr>
<tr>
<td>2705</td>
<td>Finding Unicorns Among Zebras: When and How to Test COVID-19 Patients for Underlying Immunodysregulatory Conditions</td>
<td>Saturday, February 27, 2021, 3:45 to 4:45 pm</td>
<td>Finding Unicorns Among Zebras: When and How to Test COVID-19 Patients for Underlying Immunodysregulatory Conditions</td>
</tr>
<tr>
<td>2706</td>
<td>Assessing and Improving Quality of Life in Families Affected by Food Allergy</td>
<td>Saturday, February 27, 2021, 3:45 to 4:45 pm</td>
<td>Assessing and Improving Quality of Life in Families Affected by Food Allergy</td>
</tr>
<tr>
<td>2710</td>
<td>The Journal of Allergy and Clinical Immunology (JACI): In Practice Year-in-Review Workshop</td>
<td>Saturday, February 27, 2021, 3:45 to 5:00 pm</td>
<td>The Journal of Allergy and Clinical Immunology (JACI): In Practice Year-in-Review Workshop</td>
</tr>
<tr>
<td>2711</td>
<td>Clinical, Academic and Other Features Provided by a National Allergy Bureau (NAB) Counting Station</td>
<td>Saturday, February 27, 2021, 3:45 to 5:00 pm</td>
<td>Clinical, Academic and Other Features Provided by a National Allergy Bureau (NAB) Counting Station</td>
</tr>
<tr>
<td>2712</td>
<td>Is Bitter Better for Asthma and Chronic Rhinosinusitis (CRS)?</td>
<td>Saturday, February 27, 2021, 3:45 to 5:00 pm</td>
<td>Is Bitter Better for Asthma and Chronic Rhinosinusitis (CRS)?</td>
</tr>
<tr>
<td>2713</td>
<td>Allied Health: Approach to Angioedema: Case-Based Learning</td>
<td>Saturday, February 27, 2021, 3:45 to 5:00 pm</td>
<td>Allied Health: Approach to Angioedema: Case-Based Learning</td>
</tr>
<tr>
<td>2714</td>
<td>Allied Health: Troubleshooting with Subcutaneous Immunoglobulin</td>
<td>Saturday, February 27, 2021, 3:45 to 5:00 pm</td>
<td>Allied Health: Troubleshooting with Subcutaneous Immunoglobulin</td>
</tr>
<tr>
<td>2715</td>
<td>Motivational Interviewing, Communication Skills and Hands-On Training to Improve Asthma Adherence and Outcomes</td>
<td>Saturday, February 27, 2021, 3:45 to 5:00 pm</td>
<td>Motivational Interviewing, Communication Skills and Hands-On Training to Improve Asthma Adherence and Outcomes</td>
</tr>
<tr>
<td>2716</td>
<td>Interesting Case Reports I</td>
<td>Saturday, February 27, 2021, 3:45 to 5:00 pm</td>
<td>Interesting Case Reports I</td>
</tr>
<tr>
<td>2801</td>
<td>The Best of Anaphylaxis, Dermatology and Drug Allergy</td>
<td>Saturday, February 27, 2021, 5:10 to 6:25 pm</td>
<td>The Best of Anaphylaxis, Dermatology and Drug Allergy</td>
</tr>
<tr>
<td>2802</td>
<td>Asthma Pathophysiology, Epidemiology, and Treatment</td>
<td>Saturday, February 27, 2021, 5:10 to 6:25 pm</td>
<td>Asthma Pathophysiology, Epidemiology, and Treatment</td>
</tr>
<tr>
<td>2803</td>
<td>The Best of Basic and Clinical Immunology</td>
<td>Saturday, February 27, 2021, 5:10 to 6:25 pm</td>
<td>The Best of Basic and Clinical Immunology</td>
</tr>
<tr>
<td>2804</td>
<td>Cells and Molecules of Allergic Inflammation</td>
<td>Saturday, February 27, 2021, 5:10 to 6:25 pm</td>
<td>Cells and Molecules of Allergic Inflammation</td>
</tr>
<tr>
<td>2805</td>
<td>Biologics in Allergic and Respiratory Disease</td>
<td>Saturday, February 27, 2021, 5:10 to 6:25 pm</td>
<td>Biologics in Allergic and Respiratory Disease</td>
</tr>
<tr>
<td>2806</td>
<td>Selected Allied Health Cases and Oral Abstract Sessions</td>
<td>Saturday, February 27, 2021, 5:10 to 6:25 pm</td>
<td>Selected Allied Health Cases and Oral Abstract Sessions</td>
</tr>
<tr>
<td>2807</td>
<td>Late Breaking Oral Abstract Session</td>
<td>Saturday, February 27, 2021, 5:10 to 6:25 pm</td>
<td>Late Breaking Oral Abstract Session</td>
</tr>
</tbody>
</table>

## Sunday, February 28, 2021

All times are listed in Central Standard Time (CST)

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Session Title</th>
<th>Date Time</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3001</td>
<td>Anaphylaxis in Infants</td>
<td>Sunday, February 28, 2021, 8:00 to 9:00 am</td>
<td>Anaphylaxis in Infants</td>
</tr>
<tr>
<td>3002</td>
<td>Asthma in Older Adults: A Different Disease</td>
<td>Sunday, February 28, 2021, 8:00 to 9:00 am</td>
<td>Asthma in Older Adults: A Different Disease</td>
</tr>
<tr>
<td>3003</td>
<td>Allied Health: Atopic Dermatitis: Bring Your Challenges!</td>
<td>Sunday, February 28, 2021, 8:00 to 9:00 am</td>
<td>Allied Health: Atopic Dermatitis: Bring Your Challenges!</td>
</tr>
<tr>
<td>3004</td>
<td>When Low T Cell Receptor Excision Circles Don’t Equal Severe Combined Immunodeficiency: Idiopathic T Lymphopenia and More</td>
<td>Sunday, February 28, 2021, 8:00 to 9:00 am</td>
<td>When Low T Cell Receptor Excision Circles Don’t Equal Severe Combined Immunodeficiency: Idiopathic T Lymphopenia and More</td>
</tr>
<tr>
<td>3005</td>
<td>Group 2 Innate Lymphoid Cell (ILC2) Identification: Are They What We Think They Are?</td>
<td>Sunday, February 28, 2021, 8:00 to 9:00 am</td>
<td>Group 2 Innate Lymphoid Cell (ILC2) Identification: Are They What We Think They Are?</td>
</tr>
<tr>
<td>3006</td>
<td>Air Sampling and Analysis: Current Approaches and Future Developments</td>
<td>Sunday, February 28, 2021, 8:00 to 9:00 am</td>
<td>Air Sampling and Analysis: Current Approaches and Future Developments</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 9:10 to 10:40 am</td>
<td>Eosinophilic Esophagitis from Bench to Bedside</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 12:20 to 1:35 pm</td>
<td>EAACI: Novel Avenues for Immune Modulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 12:20 to 1:35 pm</td>
<td>National Heart, Lung, and Blood Institute (NHLBI): Discovery to Application: Translational Research in Asthma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 12:20 to 1:35 pm</td>
<td>Understanding and Interpretation of Genetic Testing in the Evaluation of Primary Immunodeficiency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 12:20 to 1:35 pm</td>
<td>Immune Responses to Key Respiratory Viral Illnesses: COVID-19, Respiratory Syncytial Virus (RSV) and Rhinovirus (RV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 12:20 to 1:35 pm</td>
<td>Allergic Reactions to COVID-19 Vaccines: Differentiating Fact from Fiction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 1:45 to 3:15 pm</td>
<td>Current and Emerging Therapeutics in Upper Airway Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 3:45 to 4:45 pm</td>
<td>Reviewing the 2017 ATS Updates to the 2005 ATS/ERS Guidelines: How to Perform, Interpret and Report Spirometry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 3:45 to 4:45 pm</td>
<td>When, How and What to Feed: Practical Approach to Infants at High Risk for Food Allergy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 3:45 to 4:45 pm</td>
<td>Advanced Therapy for Urticaria: Practical Implications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 3:45 to 4:45 pm</td>
<td>Prostaglandin Regulation of Allergic Inflammation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 3:45 to 4:45 pm</td>
<td>What to Do with a Patient with Severe Chronic Rhinosinusitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, February 28, 2021, 3:45 to 4:45 pm</td>
<td>Allied Health: Maybe It's More than Asthma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Monday, March 1, 2021, continued

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>4101</td>
<td>9:10 am to 10:40 am</td>
<td>Incorporating New and Emerging Therapies into Atopic Dermatitis Practice</td>
</tr>
<tr>
<td>4301</td>
<td>11:10 am to 12:40 pm</td>
<td>The Role of Immunoglobulin E (IgE) in Primary Immunodeficiency Disorders</td>
</tr>
<tr>
<td>4401</td>
<td>12:50 pm to 2:05 pm</td>
<td>Cost Effectiveness of Biologic Therapy for Asthma</td>
</tr>
<tr>
<td>4402</td>
<td>12:50 pm to 2:05 pm</td>
<td>Is Choosing Wisely a Way to Save Allergy?</td>
</tr>
<tr>
<td>4403</td>
<td>12:50 pm to 2:05 pm</td>
<td>Many Roads to Atopic Dermatitis: Roles of the Immune System, Microbiome and the Microenvironment</td>
</tr>
<tr>
<td>4404</td>
<td>12:50 pm to 2:05 pm</td>
<td>An Update on Ocular Allergy (OA) Diagnosis and Treatment</td>
</tr>
<tr>
<td>4501</td>
<td>2:45 pm to 3:45 pm</td>
<td>Pathways to Success on a Clinician Educator Track</td>
</tr>
<tr>
<td>4502</td>
<td>2:45 pm to 3:45 pm</td>
<td>Basophil and Mast Cell Activation Tests in the Diagnosis of Allergies</td>
</tr>
<tr>
<td>4503</td>
<td>2:45 pm to 3:45 pm</td>
<td>Using Component Based Diagnostics and Effective Allergen Doses for Diagnosis and Subcutaneous Immunotherapy Treatment</td>
</tr>
<tr>
<td>4504</td>
<td>2:45 pm to 3:45 pm</td>
<td>Approach to the Patient with Eosinophilia</td>
</tr>
<tr>
<td>4505</td>
<td>2:45 pm to 3:45 pm</td>
<td>Non-Eosinophilic Asthma: Novel Biomarkers and Potential Therapeutic Targets</td>
</tr>
<tr>
<td>4506</td>
<td>2:45 pm to 3:45 pm</td>
<td>Working Through Racial Disparities in Food Allergy: A Hands-On Workshop</td>
</tr>
<tr>
<td>4507</td>
<td>2:45 pm to 3:45 pm</td>
<td>Immunodeficiency Beyond the Infections</td>
</tr>
<tr>
<td>4508</td>
<td>2:45 pm to 3:45 pm</td>
<td>Telemedicine During the COVID-19 Pandemic: What We Learned and Where Do We Go From Here?</td>
</tr>
<tr>
<td>4509</td>
<td>2:45 pm to 3:45 pm</td>
<td>Novel Mechanisms of Innate Lymphoid Cells in Asthma</td>
</tr>
<tr>
<td>4510</td>
<td>2:45 pm to 3:45 pm</td>
<td>Biologic Therapy Throughout Childhood</td>
</tr>
<tr>
<td>4511</td>
<td>2:45 pm to 3:45 pm</td>
<td>The National Asthma Education and Prevention Program (NAEPP) and Global Initiative for Asthma (GINA) Asthma Guidelines: Similar But Not the Same: How Do I Implement into My Practice?</td>
</tr>
</tbody>
</table>
Exhibitor Listing

AbbVie BSG/Medical
Accredo
ADMA Biologics
Aimmune Therapeutics
Ajinomoto Cambrooke
AllergyEHR a division of Meditab Software, Inc.
ALK-Abelló, Inc.
American Board of Allergy and Immunology
American Partnership for Eosinophilic Disorders
Asthma and Allergy Foundation of America
AstraZeneca
BioCryst Pharmaceuticals, Inc.
Blueprint Medicines
Bristol Myers Squibb
Clinical Immunology Society
CSL Behring
CuraScript SD
DBV Technologies
Edge Pharma Allergy
Eurofins Viracor
European Academy of Allergy and Clinical Immunology
Food Allergy Research & Education
Fresenius Kabi USA LLC
Genentech - Novartis
GSK - Respiratory
Helen of Troy
HollisterStier Allergy

Horizon Therapeutics
Immune Epitope Database and Analysis Resource
Incyte Corporation
International FPIES Association (I-FPIES)
Lincoln Diagnostics, Inc.
Med Learning Group
Merck & Co.
Micro Direct, Inc.
ModuleMD
MotherToBaby Pregnancy Studies
Novartis Pharmaceuticals
Nutricia North America
Optinose
Pfizer
Phadia AB, Thermo Fisher Scientific
Pharming Healthcare Inc.
RB/Mead Johnson Nutrition
Regeneron and Sanofi Genzyme
SmartPractice
Stallergenes Greer
Takeda
Teva Pharmaceuticals
US Hereditary Angioedema Association
Vitalograph, Inc.
World Allergy Organization (WAO)
X4 Pharmaceuticals
APPROVED IN

3 INDICATIONS
EXPLORE Dupixent®
(dupilumab)
AND SEE THE DATA AT OUR AAAAI VIRTUAL BOOTH

VISIT DupixentHCP.com/congress
DUPIXENT®
(dupilumab)

APPROVED IN
3 INDICATIONS

SEE THE DATA AT OUR
AAAAI VIRTUAL BOOTH

VISIT DupixentHCP.com/congress